SEC Form 4 · accession 0001104659-19-003723
Osmotica Pharmaceuticals plc · OSMT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Andrew J. Einhorn
Officer — Chief Financial Officer
Period of report
Jan 24, 2019
Accepted (ET)
Jan 28, 2019 · 5:49 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001739426
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1 | Jan 24, 2019 | A | 104,849 | $0.00 | A | 104,849 | D | |
| Ordinary SharesF2 | holding | — | — | — | 22,852 | I | By family limited liability company |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents a grant of restricted stock units.
- F2The Reporting Person is the sole managing member of the limited liability company and, as a result, may be deemed to beneficially own the ordinary shares held by the limited liability company. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein.